Ved Srivastava, PhDVice President of Peptide Chemistry at Aktis Oncology
Dr. Ved Srivastava is Vice President of Peptide Chemistry at Atkis Oncology. Prior to that, he was the Head of Peptide Chemistry at Intarcia Therapeutics and GlaxoSmithKline, USA; and in the leadership role at Amylin Pharmaceuticals (Astra Zeneca), USA. Ved is President-Elect of the American Peptide Society.
Ved has significantly participated in the development and commercialization of SymlinTM, ByettaTM, and BydeureonTM, first-in-class medicines for the treatment of diabetes. Ved has over 25 years of experience with expertise in drug discovery and development in metabolic diseases, CNS, and inflammation with major emphasis in peptide medicinal chemistry, peptide drug delivery and chemistry manufacturing and control (CMC). Ved is the Editor of four books (1) Peptide-based Drug Discovery - Challenges and New Therapeutics, (2) Comprehensive Medicinal Chemistry IIIrd edition, Volume 6. Biologics Medicine (3) ‘Peptide 2015’ and (4) Peptide Therapeutics: Strategy and Tactics for Chemistry Manufacturing and Control (in print). Ved earned a Ph.D. in organic chemistry from the University of Lucknow, India.